Literature DB >> 16699497

Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis.

Shuji Ogino1, Mohan Brahmandam, Takako Kawasaki, Gregory J Kirkner, Massimo Loda, Charles S Fuchs.   

Abstract

Transcriptional inactivation of tumor-suppressor genes by promoter CpG island methylation is thought to be an important mechanism in human carcinogenesis. The CpG island methylator phenotype (CIMP) with extensive promoter methylation appears to be a distinct epigenetic subtype of colorectal carcinoma. Most previous studies on CpG island methylation in colorectal carcinoma used methylation-specific PCR, which may detect low levels of DNA methylation with little or no biological significance. In contrast, quantitative DNA methylation assays have been shown to provide useful information beyond that which can be achieved with methylation-specific PCR. Synchronous neoplasias provide a unique model for investigators to examine molecular alterations in multistep tumorigenesis within one individual. However, no study to date has quantified DNA methylation of CIMP-specific promoters in synchronous colorectal neoplasias. Utilizing real-time PCR (MethyLight), we quantified DNA methylation in five CIMP-specific gene promoters [CACNA1G (calcium channel, voltage-dependent, T type alpha-1G subunit), CDKN2A (p16/INK4A), CRABP1 (cellular retinoic acid binding protein-1), MLH1 and NEUROG1 (neurogenin 1)] and MGMT in six synchronous carcinoma pairs (12 carcinomas) and eight synchronous carcinoma and adenoma pairs (16 tumors). We found that while some synchronous tumor pairs showed discordant promoter methylation patterns, other tumor pairs showed similar, but not exactly identical, patterns of promoter methylation. All but two pairs showed concordant patterns of CIMP status (CIMP positive vs CIMP negative) (P = 0.05 in cancer pairs). BRAF mutations were present in only CIMP-positive tumors. A high degree of microsatellite instability (MSI-H) was observed in both CIMP-positive and CIMP-negative tumors. KRAS mutations were not concordant in any synchronous neoplasia pair. In conclusion, epigenetic alterations at CIMP-specific promoter CpG islands in synchronous colorectal neoplasias likely have both random and nonrandom components.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16699497     DOI: 10.1038/modpathol.3800618

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  18 in total

1.  Comparative genomic analysis of primary versus metastatic colorectal carcinomas.

Authors:  Efsevia Vakiani; Manickam Janakiraman; Ronglai Shen; Rileen Sinha; Zhaoshi Zeng; Jinru Shia; Andrea Cercek; Nancy Kemeny; Michael D'Angelica; Agnes Viale; Adriana Heguy; Philip Paty; Timothy A Chan; Leonard B Saltz; Martin Weiser; David B Solit
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

Review 2.  Molecular classification and correlates in colorectal cancer.

Authors:  Shuji Ogino; Ajay Goel
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

Review 3.  Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression.

Authors:  Paul Lochhead; Andrew T Chan; Reiko Nishihara; Charles S Fuchs; Andrew H Beck; Edward Giovannucci; Shuji Ogino
Journal:  Mod Pathol       Date:  2014-06-13       Impact factor: 7.842

4.  Cilengitide response in ultra-low passage glioblastoma cell lines: relation to molecular markers.

Authors:  Christina S Mullins; Julia Schubert; Björn Schneider; Michael Linnebacher; Carl F Classen
Journal:  J Cancer Res Clin Oncol       Date:  2013-06-08       Impact factor: 4.553

5.  Concordant DNA methylation in synchronous colorectal carcinomas.

Authors:  Kazuo Konishi; Lanlan Shen; Jaroslav Jelinek; Yoshiyuki Watanabe; Saira Ahmed; Kazuhiro Kaneko; Mari Kogo; Toshihumi Takano; Michio Imawari; Stanley R Hamilton; Jean-Pierre J Issa
Journal:  Cancer Prev Res (Phila)       Date:  2009-09-08

6.  A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers.

Authors:  Katsuhiko Nosho; Shoko Kure; Natsumi Irahara; Kaori Shima; Yoshifumi Baba; Donna Spiegelman; Jeffrey A Meyerhardt; Edward L Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Gastroenterology       Date:  2009-08-14       Impact factor: 22.682

7.  Braf, Kras and Helicobacter pylori epigenetic changes-associated chronic gastritis in Egyptian patients with and without gastric cancer.

Authors:  Dina Sabry; Rasha Ahmed; Sayed Abdalla; Wael Fathy; Ahmed Eldemery; Azza Elamir
Journal:  World J Microbiol Biotechnol       Date:  2016-04-27       Impact factor: 3.312

8.  KRAS mutation status is highly homogeneous between areas of the primary tumor and the corresponding metastasis of colorectal adenocarcinomas: one less problem in patient care.

Authors:  Mariana Petaccia de Macedo; Fernanda M Melo; Heber Salvador C Ribeiro; Marcio C Marques; Luciane T Kagohara; Maria Dirlei Begnami; Julio C Neto; Júlia S Ribeiro; Fernando A Soares; Dirce M Carraro; Isabela W Cunha
Journal:  Am J Cancer Res       Date:  2017-09-01       Impact factor: 6.166

9.  The pleiotropic phenotype of Apc mutations in the mouse: allele specificity and effects of the genetic background.

Authors:  Richard B Halberg; Xiaodi Chen; James M Amos-Landgraf; Alanna White; Kristin Rasmussen; Linda Clipson; Cheri Pasch; Ruth Sullivan; Henry C Pitot; William F Dove
Journal:  Genetics       Date:  2008-08-24       Impact factor: 4.562

10.  Aberrant gene promoter methylation associated with sporadic multiple colorectal cancer.

Authors:  Victoria Gonzalo; Juan José Lozano; Jenifer Muñoz; Francesc Balaguer; Maria Pellisé; Cristina Rodríguez de Miguel; Montserrat Andreu; Rodrigo Jover; Xavier Llor; M Dolores Giráldez; Teresa Ocaña; Anna Serradesanferm; Virginia Alonso-Espinaco; Mireya Jimeno; Miriam Cuatrecasas; Oriol Sendino; Sergi Castellví-Bel; Antoni Castells
Journal:  PLoS One       Date:  2010-01-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.